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Abstract 26 
Until recently, proper development of molecular studies in Bifidobacterium 27 
species has been hampered by the growth difficulties, because of their exigent nutritive 28 
requirements and oxygen sensitivity, and a lack of efficient genetic tools. These 29 
studies, however, are critical to uncover the cross-talk between bifidobacteria and their 30 
hosts’ cells, and also to prove unequivocally the supposed beneficial effects they 31 
provide through endogenous bifidobacterial populations or after their ingestion as 32 
probiotics. The genome sequencing projects of different bifidobacterial strains have 33 
provided a wealth of genetic data, which will be of much help to decipher the 34 
molecular basis of the physiological properties of bifidobacteria. To this end, the 35 
purposeful development of stable cloning and expression vectors based on robust 36 
replicons –either from temperate phages or resident plasmids– is still needed. This 37 
review addresses the current knowledge on the mobile genetic elements of 38 
bifidobacteria (prophages, plasmids, and transposons) and summarizes the different 39 
types of vectors already available, together with the transformation procedures for 40 
introducing DNA into the cells. It also covers recent molecular studies performed with 41 
such vectors and incipient results on the genetic modification of these organisms, 42 
establishing the basis that would allow the use of bifidobacteria for future 43 
biotechnological applications. 44 
 45 
1. General introduction 46 
The members of the genus Bifidobacterium are anaerobic, fermentative bacteria, 47 
high G+C, Gram-positive bacteria belonging to order Bifidobacteriales inside the 48 
phylum Actinobacteria (Scardovi, 1986). Bifidobacterial species form a coherent 49 
phylogenetic group showing over 93% similarity of the 16S rRNA sequences among 50 
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them. At present, more than 40 species are included in the genus Bifidobacterium 51 
(http://old.dsmz.de/microorganisms/bacterial_nomenclature_info.php?genus=Bifidoba52 
cterium), of which B. adolescentis, B. angulatum, B. breve, B. bifidum, B. catenulatum, 53 
B. dentium, B. longum, and B. pseudocatenolatum are dominant Bifidobacterium 54 
species in the human gastrointestinal tract (GIT) (Fanaro et al., 2003; Mueller et al., 55 
2006). These and B. animalis subsp. lactis, the typical species isolated from functional 56 
foods (Masco et al., 2005), are therefore the first target for health-related studies. 57 
Bifidobacteria are considered to exert a vast array of beneficial health effects, 58 
including the establishment of healthy microbiota in infants, competitive exclusion 59 
against intestinal pathogens, and modulation of the immune functions (Leahy et al., 60 
2005; Turroni et al., 2009). In humans, bifidobacteria represent up to 90 % of the total 61 
gut microbiota in breast-fed babies (Fanaro et al., 2003; Turroni et al., 2012) and up to 62 
5 % in healthy adults (Mueller et al., 2006; Claesson et al., 2011). The colonization of 63 
human intestinal tract by bifidobacteria starts soon after birth and lasts all lifelong. 64 
Thus, unsurprisingly bifidobacteria have become a common component of probiotic 65 
products designed for human or animal consumption (Tuohy et al., 2003; Leahy et al., 66 
2005; Parvez et al., 2006). Probiotic products represent a strong growth area within the 67 
functional foods market and are currently having a significant economic impact on the 68 
dairy sector. However, ‘long-term exploitation of probiotics as health promoters is 69 
dependent on several factors, including sound, scientifically-proven clinical evidence 70 
of health-promoting activity, accurate consumer information, effective marketing 71 
strategies, and, above all, a quality product that fills consumer expectations’ (Stanton et 72 
al., 2001). While clinical evidence for the purported beneficial effects is rapidly 73 
accumulating (Tuohy et al., 2003; Leahy et al., 2005; Guglielmetti et al., 2011; 74 
Guglielmetti et al., 2011; Ishikawa et al., 2011), there still is a lack of fundamental 75 
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knowledge on the molecular mechanisms by which bifidobacteria interact with other 76 
bacteria and their hosts, while contributing to their health and well-being (Kullen and 77 
Klaenhammer, 2000; Ventura et al., 2009). 78 
 79 
2. Genetics of bifidobacteria 80 
Compared with other microbes of industrial importance, the genetics of 81 
bifidobacteria is poorly understood (Ventura et al., 2004). Bifidobacteria are difficult to 82 
handle in the laboratory because they are exigent microorganisms demanding for 83 
growth rich media and requiring strict anaerobic conditions (Scardovi, 1986). In 84 
addition, genetic studies have further been hampered by a lack of appropriate bacterial 85 
replicons (of either plasmid or phage origin), with which to construct suitable genetic 86 
tools. Moreover, until recently, bifidobacteria were considered recalcitrant to 87 
transformation, and genetic engineering techniques were simply unknown. 88 
In the last decade, whole genome sequencing has revolutionized the genetic, 89 
biochemical, and molecular biological research in bacteria and in many higher 90 
organisms, constituting an essential step for generating primary genetic information for 91 
downstream functional applications, such as comparative genomics, transcriptomics, 92 
and/or proteomics, which in turn can address fundamental and applied questions. 93 
Specifically, operons and genes encoding several cell envelope-associated structures, 94 
such as exopolysaccharides (EPS) (Schell et al., 2002; Barrangou et al., 2009; Ventura 95 
et al., 2009b), fimbriae-like glycoproteins (Schell et al., 2002; Ventura et al., 2009b), 96 
serpin-like protease inhibitors (Ivanov et al., 2006; Turroni et al., 2010), adhesins 97 
(Guglielmetti et al., 2008b), and pilus-like structures (Foroni et al., 2011; O’Connell 98 
Motherway et al., 2011a), have been identified. In addition, genes dealing with diverse 99 
stresses that bifidobacteria face in their environment (acid, bile), genes encoding 100 
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adaptive functions to the intestinal niche, or others contributing to ecological fitness 101 
have also been identified (Schell et al., 2002; Sela et al., 2008; Barrangou et al., 2009; 102 
Kim et al., 2009). Concerning the adaptation to intestinal environmental, largely the 103 
best studied bifidobacterial strain is B. breve UCC2003, thanks to the molecular and 104 
functional characterization of many genetic loci, which have been identified in its 105 
genome (O'Connell et al., 2008; Zomer and van Sinderen, 2010; O'Connell Motherway 106 
et al., 2011a; O'Connell Motherway et al., 2011b; Pokusaeva et al., 2011; Fanning et 107 
al., 2012; Ruiz et al., 2012). 108 
Up till now, the genome sequences publically available of 17 Bifidobacterium 109 
strains belonging to five species, namely B. adolescentis, B. animalis subsp. lactis, B. 110 
bifidum, B. dentium, and B. longum of both infantis and longum subspecies, have all 111 
been concluded and analysed (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). In 112 
addition, many other Bifidobacterium genome projects are in progress worldwide and, 113 
due to the progressive cost reduction of the sequencing technologies, this list is 114 
exponentially growing. To manage this enormous wealth of genetic data and prove 115 
unequivocally the biological role of each particular operon or gene, cloning, 116 
expression, knock-out, and transfer of the determinants are needed. To these aims, 117 
suitable vectors and other genetic tools based on the replication units and insertional 118 
machinery of phages, plasmids and/or transposons are essential. 119 
 120 
3. The mobilome of bifidobacteria 121 
Genomes are the result of the adaptive evolution of microorganisms to their 122 
ecological niche (Ventura et al., 2007). In this context, various genetic events, such as 123 
gene duplication, horizontal gene transfer (HGT), gene decay, and chromosomal 124 
rearrangements, have determined the shape of bacterial genomes. As suggested by 125 
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Philippe and Douady (2003), plasmids, bacteriophages (phages), and transposons are 126 
considered major agents for shaping the bifidobacterial genomes through horizontal 127 
gene transfer (HGT) processes. The above mentioned mobile genetic elements, as well 128 
as others, such as group II introns and jumping genes, constitute what has recently been 129 
defined as the mobilome (Frost et al., 2005; Siefert, 2009). 130 
 131 
3.1. Plasmids of bifidobacteria 132 
Plasmids are extra-chromosomal, autonomously replicating genetic elements 133 
found in bacteria, archaea, and eukaryotic cells. Despite their independent replication, 134 
plasmids make use of cellular enzymes to ensure both replication and maintenance 135 
(Hayes, 2003). Plasmids display an enormous diversity of features, such as size, host 136 
range, and the repertoire of genes that they carry. By definition, plasmids do not 137 
encode essential genes for growth, nonetheless they can provide a wide variety of 138 
phenotypes to the cells that harbour them, including antibiotic resistance, bacteriocin 139 
production, virulence and pathogenesis or degradation of complex and recalcitrant 140 
(toxic) compounds found in some ecosystems. They can also encode for the ability to 141 
use carbohydrates and/or protein substances as a source of carbon and energy (Thomas 142 
et al., 2004). All these properties have endowed plasmids with the title of primarily 143 
adaptative entities (Siezen et al., 2005). Apart from the traits with an impact on host 144 
physiology and ecology, important characteristics of plasmids include copy number 145 
(low, medium, high), host range (narrow, broad), and capability to spread (conjugation, 146 
mobilization) (Hayes, 2003). Small plasmids (i.e. smaller than 15-20 kb in size) often 147 
do not encode any selectable trait and are therefore denominated “cryptic”. It seems, 148 
however, plausible to presume that they simply benefit its host by promoting 149 
recombination and, consequently, enhance the ecological adaptability of the bacterial 150 
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population (Guglielmetti et al., 2007a; Thomas et al., 2004). Plasmids can be, 151 
consequently, depicted as accessory and/or adaptive gene pools shared by bacteria. 152 
Analyses of bifidobacteria have indicated that extrachromosomal elements are 153 
scarcer than in other intestinal bacterial species (Sgorbati et al., 1982; Iwata and 154 
Morishita, 1989; Park et al., 1997) and, where found, they have a size generally smaller 155 
than 15 kb. Strains from the species B. longum subsp. longum (hereafter B. longum, if 156 
not differently specified), B. globosum, B. asteroides, and B. indicum seem to harbour 157 
more plasmids than those from other species (Sgorbati et al., 1982). At present, the 158 
nucleotidic sequence of more than 30 bifidobacterial plasmid molecules is available in 159 
GenBank (Table 1; http://www.ncbi.nlm.nih.gov/sites/entrez/). The majority of these 160 
molecules (up to 19) were isolated from B. longum strains, which includes pMB1 161 
(Rossi et al., 1996), the first plasmid to be analysed at a molecular level from a 162 
member of this genus. Three other plasmids have been characterized from strains of B. 163 
breve, two from B. asteroides and B. bifidum, and single plasmids have been analysed 164 
from strains of B. catenulatum, B. pseudocatenulatum, and B. pseudolongum subsp. 165 
globosum. The obtained sizes of the studied plasmids show a range between 1.8 kb for 166 
pMB1 to 10.2 kb for pNAC3. In most cases, strains harbour a single plasmid, except 167 
for three strains of B. longum in which two different plasmid molecules were identified 168 
(Table 1). In addition, B. longum NAL8 and B. longum FI10564 have been reported to 169 
contain three different plasmids each. The significance of these autonomously-170 
replicating DNA elements in bifidobacteria remains unclear, since no obvious 171 
phenotypic traits have been associated to plasmids, except for the production of the 172 
bacteriocin bifidocin B by B. bifidum NCFB 1454, which was associated to a 8 kb 173 
plasmid (Yildirim et al., 1999). Nevertheless, this plasmid has never been sequenced or 174 
characterized further. More recently, a further plasmid of this species (pBIF10) has 175 
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been found to contain tetQ, a gene encoding a ribosome protection protein providing 176 
tetracycline resistance (DQ093580). 177 
The basic biology of bifidobacterial plasmids remains poorly understood and most 178 
of the information derive from in silico investigation. Indeed, the mode of replication 179 
has been experimentally analysed for only a few of them (Moon et al., 2009; Park et 180 
al., 2008; Guglielmetti et al., 2007b; Lee and O’Sullivan, 2006; Corneau et al., 2004; 181 
O’Riordan and Fitzgerald, 1999; Park et al., 1999). Furthermore, dissection of open 182 
reading frames (ORFs) and analysis of untranslated sequences and structures have been 183 
undertaken for only two plasmids: pBC1 (Álvarez-Martín et al., 2007a) and pCIBA089 184 
(Cronin et al., 2007). Sequence comparison suggests that most bifidobacterial plasmids 185 
probably replicate by means of a rolling-circle mechanism, with the exception 186 
represented by eight plasmids that appear to use the theta-replicating mode (Table 1; 187 
Moon et al., 2009; Álvarez-Martín et al., 2008; Cronin et al., 2007; Klijn et al., 2006; 188 
Lee and O’Sullivan, 2006; Rossi et al., 1996). Phylogenetic analysis of their replication 189 
(Rep) initiator proteins revealed that Bifidobacterium plasmids could be clustered into 190 
six different groups (Table 1 and Fig. 1). Homology of bifidobacterial Rep proteins has 191 
shown that, in some cases, their closest relatives are found in plasmids from 192 
phylogenetically distant bacterial groups (Álvarez-Martín et al., 2007b; Guglielmetti et 193 
al., 2007b). For instance, Rep protein of plasmid pBIF10 from B. bifidum M203049 194 
(type IV) is strictly related with the replication proteins of plasmids commonly 195 
harbored by the Cytophaga–Flavobacterium–Bacteroides group of Gram-negative 196 
bacteria. The same plasmid also contains two other DNA regions, respectively of 1966 197 
and 2569 bp displaying strong similarity with genetic regions of Bacteroides intestinal 198 
strains (DQ093580). The former region includes mobilization genes mobA and mobB, 199 
while the latter comprises tetQ gene (Fig. 2). These similarities leave to suppose that 200 
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plasmid pBIF10 could have been relatively recently acquired by strain B. bifidum 201 
M203049 from Bacteroides thorough horizontal DNA transfer. 202 
More surprisingly, the Rep protein encoded by plasmid p4M from B. 203 
pseudocatenulatum VMKB4M (type VI) displays its highest level of similarity to the 204 
replication initiator protein of the eukaryotic circoviruses/cicloviruses, a feature that is 205 
unprecedented in any known bacterial plasmid (Gibbs et al., 2006). 206 
Upstream of the Rep protein, Bifidobacterium plasmids contains non-coding 207 
regions characterized by tandem direct and inverted repeats sequences, in an 208 
organization that resembles the so-called DNA iteron structures observed in the origin 209 
of replication of some theta and rolling circle replicating plasmids (del Solar et al., 210 
1998). The tandem repeat organization is similar in all plasmids but sequences of the 211 
repeats are variable, thus, conferring specific interaction between Rep proteins and 212 
DNA sequences. 213 
Differences in nucleotide sequences and gene organization have been encountered 214 
among the 30 known bifidobacterial plasmids, leading to the identification of 13 215 
different modular structures, represented by the genetic maps of characteristic plasmids 216 
shown in Fig. 2. Apart from Rep, many plasmids contains accessory ORFs encoding 217 
hypothetical proteins, some of which, such as the mobilization-like proteins (Fig. 2), 218 
may be involved, together with their accompanying oriT sequences, in plasmid spread. 219 
In a few bifidobacterial plasmids are also present putative genes encoding non-220 
essential proteins, such as OrfX and CopG, which are involved in the control of 221 
replication, copy number and/or plasmid stability (Álvarez-Martín et al., 2007a; del 222 
Solar et al., 1998). 223 
Finally, it should be mentioned that whole genome analyses of Bifidobacterium 224 
strains are revealing the presence of integrated plasmid remnants in the chromosome, 225 
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such as those discovered in B. longum NCC2705 (Schell et al., 2002) and F8 (GenBank 226 
Acc. No. FP929034). 227 
 228 
3.2. Phages of bifidobacteria 229 
Phages are widely distributed among eubacteria, where they are thought to 230 
influence the genomic evolution and adaptive capabilities of their hosts (Canchaya et 231 
al., 2003). The first report of Bifidobacterium phages dates back to 1966, when they 232 
were detected in rumen (Youseff et al., 1966). However, in this work the morphology 233 
and other characteristics of the phage particles were unreported. The work of Youse et 234 
al. was followed by an electron microscopy observation of a lytic phage from the so-235 
called B. ruminale (today reclassified as B. thermophilum) strain RU271 by Matteuzzi 236 
and Sozzi (1970). Further pioneering reports include that of Sgorbati et al. (1983), 237 
where inducible prophages from strains of B. longum were released by mitomycin C 238 
and further characterized by electron microscopy. However, no further studies on 239 
bifidobacterial phages appeared until the analysis of whole genomes. Three highly 240 
related prophage-like elements have been reported to be present in the genome of B. 241 
breve UCC2003, B. longum NCC2705, and B. longum DJO10A (Ventura et al., 2005). 242 
These elements, designated Bbr-1, Bl-1, and Blj-1 respectively, share nucleotide and 243 
organization homology with double-stranded DNA bacteriophages infecting low G+C 244 
Gram-positive bacteria, arguing for a common evolution of phages within the GIT 245 
ecosystem (Ventura et al., 2005). The Blj-1 prophage is 36.9 kb long and is excised 246 
from the chromosome when B. longum DJO10A is exposed to mitomycin C or 247 
hydrogen peroxide (Ventura et al., 2005). Thus, Blj-1 appears to constitute the first 248 
inducible prophage whose sequence is entirely known. In contrast, Bbr-1 and Bl-1 249 
elements are not inducible, suggesting they may represent non-functional prophages. 250 
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Though defective, they may still constitute functional satellite phages, whose mobility 251 
depends on helper phages in a similar manner to that described for the cryptic 252 
mycophages Rv1 and Rv2 (Hendrix et al., 1999). All three bifidobacterial prophages 253 
are integrated in a tRNAMet gene, which had not previously been shown to act as an 254 
attB site in Gram-positives (Campbell, 1992). Analysis of the distribution of this 255 
integration site in bifidobacterial species has revealed that attB sites are well 256 
conserved. In addition, in the genome of B. longum subsp. infantis ATCC 15697 and 257 
those of B. animalis subsp. lactis DSM10140 and Bl-04, prophage genes have also 258 
been encountered (Sela et al., 2008; Barrangou et al., 2009), although these remnant 259 
elements are not adjacent to tRNAMet sequences. The use of conserved attB sequences 260 
and their associated int genes might allow the construction of efficient recombination 261 
modules analogous to the Streptomyces integrative plasmid pSE211 (Brown et al., 262 
1990). This module may represent an ideal source for integration systems, enabling 263 
future development of food-grade, single copy integration of foreign DNA at specific 264 
sites within the bifidobacterial chromosome without disturbing host functions. Similar 265 
systems have been developed for lactic acid bacteria, such as lactobacilli (Martín et al., 266 
2000), and for high G+C bacteria, such as Streptomyces and Mycobacterium (Combes 267 
et al., 2002). 268 
 269 
3.3. Transposons and insertion sequence (IS) elements in bifidobacteria 270 
Transposons and IS elements are mobile genetic units that move from one to 271 
another position in the genome by a process referred to as transposition. Transposition 272 
occurs via one of two mechanisms: cut-and-paste transposition or replicative 273 
transposition (Roberts et al., 2008), leaving, respectively, one copy on the target DNA 274 
or two copies on both donor and target DNA. Both transposons and ISs are potent, 275 
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broad spectrum mutators contributing to the shape of the function, structure and 276 
dynamics of genes and genomes (Philippe and Douady, 2003). Transposons and ISs 277 
can be converted into powerful genetic tools, with which to explore the functionality of 278 
genes. In addition, transposons integrating at preferred, neutral sites can be used for 279 
genetic modification of bacteria. Sixteen IS elements of five classes have been reported 280 
to be spread in the B. longum NCC2705 genome (Schell et al., 2002). Although present 281 
at similar numbers in the genome of all other strains analyzed, ISs have not been 282 
considered in other works. An IS of 1047 bp long was identified in the upstream region 283 
of the tetracycline resistant gene tet(W) found on the chromosome of B. longum F8 284 
(Kazimierczak et al., 2006). A similar IS of 1163 bp was also found to interrupt the 285 
structural tet(W) gene in the susceptible B. longum M21 strain (Ammor et al., 2008). 286 
The tet(W) gene is also located in the chromosome of the largely diffused commercial 287 
probiotic strain B. animalis subsp. lactis BB12 and was found to be adjacent to a 288 
transposase gene (genes BIF_01560 and BIF_02030 of the annotated genome of strain 289 
BB12; Garrigues et al., 2010). However, analysis of the flanking DNA sequences 290 
shows that the tet(W) gene should not be contained in a functional mobile element. 291 
The spreading process of the ISs involves excision and integration into a new 292 
place, at which position a short nucleotide duplication is usually found. Interestingly, 293 
five out of the six bp sequences duplicated in F8 (CAATGC) seem to mirror the 5 bp 294 
duplication in M21 (GTTAC) (B. Mayo, unpublished), suggesting the presence of 295 
active insertion sites in bifidobacterial genomes. 296 
Recently, Fukiya et al. (2010) characterized an insertion sequence-like element of 297 
the IS200/IS605 family, which was inserted into a 5.0-kb pKJ50-like plasmid resulting 298 
in the size-increased cryptic plasmid pBK283 from B. longum strain BK28. The 299 
element, named ISBlo15, was 1593 bp in length and contained a single ORF encoding 300 
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a putative transposase, tnpB (Fig. 2). The same authors also reported that sequences 301 
similar to ISBlo15 are widely distributed among the nine Bifidobacterium species they 302 
tested. 303 
Finally, a copy of the transposon Tn5432, which encodes resistance to 304 
erythromycin and clindamycin, has been identified in several B. thermophilum strains 305 
isolated from pig faeces (van Hoek et al., 2008). Tn5432 was first isolated from 306 
Corynebacterium xerosis and rescued copies on plasmids were shown to be able to 307 
transpose in Corynebacterium glutamicum causing several mutations (Tauch et al., 308 
1995). The transposition ability of Tn5432 from B. thermophilum remains however to 309 
be determined. 310 
Knowledge on Bifidobacterium transposons and ISs is strongly needed, since they 311 
can bring to the development of high-efficiency transposon mutagenesis systems that 312 
could greatly facilitate the molecular study of bifidobacteria. However, tools for 313 
bifidobacteria based on these elements are yet not available. 314 
Finally, a new mobile genetic element has been described in B. longum (Schell et 315 
al., 2002; Lee et al., 2008), named mobile integrase cassette (MIC). MIC elements are 316 
constituted by a conserved 20 bp palindrome sequence and two insertion sequences 317 
separated by three contiguous but different xerC integrase genes (Lee et al., 2008). 318 
Interestingly, one MIC of the  strain B. longum DJO10A was shown to be active during 319 
the adaptation of B. longum DJO10A to in vitro fermentation conditions (continous 320 
growth up to about 1000 generations) (Lee et al., 2008). 321 
 322 
4. General and specialized vectors for bifidobacteria 323 
Some natural bifidobacterial plasmids have provided the basis for the construction 324 
of Escherichia coli–Bifidobacterium shuttle vectors, mostly resulting from the direct 325 
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cloning of whole plasmids into an E. coli vector containing selectable antibiotic 326 
resistance genes such as spectinomycin, erythromycin and chloramphenicol (Álvarez-327 
Martín et al., 2008; Guglielmetti et al., 2007b; Klijn et al., 2006; Lee and O’Sullivan, 328 
2006; Park et al., 1999; Rossi et al., 1996, 1998; Matsumura et al., 1997; Missich et al., 329 
1994; Table 13.2). In this way, the plasmid pBC1 from B. catenulatum L48 has been 330 
used for the construction of a series of E. coli–Bifidobacterium shuttle vectors with 331 
innovative characteristics such as the presence of a tetracycline resistance gene of 332 
bifidobacterial origin [tet(W)] and the cloning of the β-galactosidase complementing 333 
peptide gene for a convenient blue/white screening of recombinant clones in E. coli 334 
(Álvarez-Martín et al., 2008). The functionality of the vectors was further checked by 335 
cloning and overexpression of an α-l-arabinofuranosidase gene from B. longum B667 336 
in E. coli and Bifidobacterium strains. 337 
As plasmid maintenance constitutes a major problem for vector utilization, 338 
González Vara and co-workers studied the segregational and structural stability of 339 
pMB1–derived constructs in B. animalis by continuous culture (González Vara et al., 340 
2003). These authors reported a high correlation between instability and plasmid size, 341 
while no major deletions and rearrangements were observed. However, some 342 
constructs did not behave as expected (González Vara et al., 2003), a result that agrees 343 
with observations by other authors (Álvarez-Martín et al., 2007a), suggesting that 344 
beyond plasmid size, secondary structure of the constructs may further influence 345 
stability. 346 
It is worth noting that in spite of a limited knowledge of plasmid biology, a 347 
number of vectors for heterologous expression of desirable foreign genes have already 348 
been developed. As an example, the reporter vector pMDY23 expresses the gusA gene 349 
of E. coli (Klijn et al., 2006); vector pBES2 has been used to express the α-amylase 350 
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gene of B. adolescentis in B. longum (Rhim et al., 2006); pBLES100 (Matsumura et al., 351 
1997) has been employed for the expression of the Salmonella flagellin gene (Takata et 352 
al., 2006); and pBV22210 has been used to express the anticancer protein endostatin 353 
(Xu et al., 2007). 354 
 355 
5. Genetic modification of bifidobacteria 356 
Since the mid-eighties, research efforts have focused on establishing effective 357 
protocols for the genetic modification of bifidobacteria. Currently, 358 
electrotransformation (electroporation) of bifidobacteria by plasmid DNA is commonly 359 
being reported, whereas little or nothing is known about other recombinant DNA 360 
technologies such as conjugation. In fact, the members of the genus Bifidobacterium 361 
have traditionally been considered refractory to efficient and reproducible genetic 362 
manipulation. Potentially, several factors can contribute, to various extents in different 363 
strains, to bifidobacterial recalcitrance for acquiring exogenous DNA: (i) the presence 364 
of a thick (multi-layered) and complex cell wall (Fischer, 1987), (ii) intracellular 365 
restriction/modification barriers (Hartke et al., 1996; Schell et al., 2002; Yasui et al., 366 
2009), and (iii) sensitivity to environmental stresses (principally oxygen) during 367 
preparation of competent cells and transformation. 368 
Full exploitation of genomic data requires the use of general and specialized 369 
vectors for gene overexpression, integration, knock-out, and gene expression studies. 370 
Such molecular studies can substantiate the wide use of bifidobacteria as probiotic by 371 
explaining the molecular mechanisms governing the interaction with the host. In 372 
addition, bifidobacteria have recently been appointed as biotechnological agents for in 373 
situ production and delivery of therapeutic compounds, such as antigens (for live 374 
vaccine development) and tumour-suppressing substances (Fujimori, 2006; Xu et al., 375 
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2007), and as a means of increasing beneficial detoxifying activities into the 376 
gastrointestinal tract (Park et al., 2007). Traditional and new applications, therefore, 377 
require utilization of robust genetic tools and improved genetic transformation 378 
techniques. 379 
 380 
5.1. Genetic transformation by electroporation 381 
The first scientific proof of genuine genetic transformation of Bifidobacterium 382 
dates back to 1994, when Missich and collaborators introduced by electroporation 383 
pRM2 (Missich et al., 1994), a derivative of the small B. longum cryptic plasmid 384 
pMB1 (Sgorbati et al. 1982), into a cured B. longum strain that originally harboured the 385 
plasmid pMB1. The small theta replicating plasmid pMB1 represents, so far, the 386 
replicon most commonly used to construct Bifidobacterium vectors (Missich et al., 387 
1994). The protocols available for preparing electrocompent cells and subsequent 388 
electroporation are based mainly on the comprehensive studies by Argnani et al. (1996) 389 
and Rossi et al. (1997), who considered and optimized several conditions such as 390 
growth medium, washing solutions, incubation temperatures, and voltage. 391 
 392 
5.1.1. Preparation of electro-competent cells 393 
The preparation of electro-competent bacterial cells consists in weakening the cell 394 
wall and making the bacteria permeable to DNA during an electrical discharge while 395 
preserving their viability. The general strategies for achieving this goal comprise use of 396 
bacterial cells in the exponential growth phase, growth in presence of high sugar 397 
concentration, osmotic stabilizers in washing and electroporation buffers, or 398 
maintaining cells at low temperature. 399 
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Growth phase. Since the composition of the cell wall plays a key role in DNA 400 
uptake, numerous studies have reported the importance of harvesting bacterial cells at a 401 
specific stage of their growth. Some studies showed that bifidobacteria could be 402 
effectively transformed only when they were in the early exponential phase (OD600 nm 403 
0.2-0.4) (Missich et al., 1994; Argnani et al., 1996; Rossi et al., 1997), whereas 404 
efficiencies dropped for older cells, reaching zero for cells from the stationary growth 405 
phase (Rossi et al., 1997). In contrast, other researchers have observed maximal 406 
transformation efficiency with cells in the middle to late log phase. For instance, 407 
Matsumura et al. found that with the vector pBLESS100 the transformation efficiency 408 
of B. longum 105-A was about one order of magnitude higher when cells were 409 
approaching the stationary phase as compared to early-log phase (Matsumura et al., 410 
1997). Similarly, in more recent studies, midlogarithmic-phase cells were used (optical 411 
density at 600 nm 0.5 to 0.7) to effectively transform different Bifidobacterium species 412 
(MacConaill et al. 2003; Cronin et al., 2007; Sangrador-Vegas et al., 2007; Álvarez 413 
Martín et al., 2008). 414 
Growth media. The addition to the growth medium of sugars in high 415 
concentrations is traditionally recognized as an effective strategy to improve the 416 
transformation yield by affecting the composition of the cell wall. Argnani and 417 
collaborators (1997) cultivated the cells in MRS broth supplemented with 0.5 M 418 
sucrose and washed them in a buffered sucrose solution at the same concentration. 419 
Rossi et al. (1996) showed a 100-fold increase in transformation efficiency when 420 
Bifidobacterium cells were grown in Iwata medium (IM) supplemented with raffinose 421 
0.3 M or, especially, 16% Actilight®P, as compared with cells grown in IM broth with 422 
or without glucose. Actilight®P is a commercial product comprising a mix of short-423 
chain fructooligosaccharides (1-kestose, nystose, and fructosylnystose; FOS), which 424 
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are metabolised by bifidobacteria and may protect cells from stress (Guglielmetti et al., 425 
2008a). Using this sugar product in a growth broth and washing buffer can thus 426 
improve transformation efficacy by preserving the cells’ physiological condition 427 
during the preparation of competent bifidobacteria. This statement has been recent 428 
confirmed in a study, in which the use of 16% FOS or 10% GOS allowed the 429 
transformation of B. bifidum and B. asteroides, two bifidobcaterial species known for 430 
their recalcitrance for acquiring exogenous DNA (Serafini et al., 2012). 431 
Electroporation buffers. Argnani and collaborators showed that a few-hour storage 432 
of bacterial cells before electroporation at 4 °C in an electroporation buffer composed 433 
of 0.5 M sucrose, 1 mM ammonium citrate, pH 6, significantly improved the 434 
transformation efficiency of bifidobacteria. Argnani et al. (1997) suggested that in the 435 
conditions they had established, the presence of low-molarity ammonium citrate (more 436 
than HEPES and phosphate buffers) as the osmotic stabilizer may support the right 437 
degree of cell autolysis without limiting cell viability, resulting in improved cell wall 438 
permeability for exogenous DNA. In addition, Rossi and collaborators showed the 439 
importance of the incubation step in the electroporation buffer at 0°C overnight (Rossi 440 
et al., 1997). Their electroporation buffer, named KMR, was composed of KH2PO4 5 441 
mM, MgCl2 1 mM and raffinose 0.3 M, pH 4·8. However, the higher salt concentration 442 
of the KMR buffer may favour arcing events during the electrical discharge (S. 443 
Guglielmetti, unpublished). 444 
 445 
5.1.2. Efficiency of electro-transformation in bifidobacteria 446 
In general, the rate of electroporation-mediated transformation in bifidobacteria is 447 
extremely low and constitutes the main limitation on successfully applying traditional 448 
genetic manipulation strategies to members of this genus. Wide variation in 449 
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transformation efficiencies have been reported in the literature, ranging from about 100 450 
(e.g., Rossi et al., 1997) to more than 106 (e.g., Tanaka et al., 2005) transformants per 451 
µg of recombinant DNA (Table 2). Besides the protocols adopted for preparing 452 
competent cells and subsequent electroporation, considerable differences can be 453 
obtained depending on the strain under study (see Table 2). Nonetheless, valuable 454 
progress has recently been made in improving transformation rates, thanks to studies 455 
on the restriction/modification systems of bifidobacteria, which have been shown to be 456 
the main obstacle in the acquisition of foreign DNA by these bacteria. 457 
 458 
5.1.3. Optimization strategies for the electro-transformation of bifidobacteria 459 
To improve efficiency it is crucial to preserve cell viability during electroporation. 460 
One main reason for cell mortality during these experiments is oxidative stress. To 461 
overcome this problem, Park and colleagues added Oxyrase®, and enzyme system 462 
removing oxygen from its environment, to the incubation buffer after the electric pulse 463 
was given to the competent cells. This strategy allowed B. longum MG1 to transform at 464 
100-fold improved electroporation efficiency (Park et al., 2003). 465 
In general, DNA introduced into bacteria by electroporation is more vulnerable to 466 
restriction nucleases than that transferred by conjugation or natural transformation. 467 
This is particularly important for bifidobacteria, whose perhaps most immediate 468 
obstacle to acquiring exogenous DNA are their restriction/modification (R-M) systems. 469 
DNA R-M gene clusters coding for methyltransferases and restriction enzymes can be 470 
recognized in all sequenced bifidobacterial genomes, and to date several proven or 471 
potential R-M systems belonging to either Type I, II, and IV have already been 472 
identified (Roberts, 1980; Hartke et al., 1996; Schell et al., 2002; Lee et al., 2008; 473 
O’Connell-Motherway et al., 2009; Yasui et al., 2009; http://rebase.neb.com/rebase). 474 
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Based on the above, several studies have reported a significant increase in 475 
transformation efficiency when transformed DNA has been isolated from 476 
Bifidobacterium instead of E. coli (Rossi et al., 1997; Rossi et al., 1998; O’Connell-477 
Motherway et al., 2009; Yasui et al., 2009). For instance, Rossi et al. (1998), found that 478 
only vector DNA prepared from bifidobacteria could successfully transform some 479 
strains of B. longum, B. animalis, or B. bifidum. Therefore, proper modification of 480 
plasmid DNA can help to bypass the restriction barriers and favour the acquisition of 481 
foreign recombinant DNA by bifidobacteria. This assumption has been verified by a 482 
recent study, in which site-directed mutagenesis and in vitro methylation were applied 483 
to remove or modify restriction sites from a vector pYBamy59 before 484 
electrotransformation into B. longum MG1 (Kim et al., 2010). In this study, sequence 485 
analysis of pYBamy59 fragments originated by incubation of recombinant DNA with 486 
cell extracts of MG1, revealed the presence of a SacII-like endonuclease activity, 487 
recognizing the palindromic sequence 5’-CCGCGG-3’. When pYBamy59 from E. coli 488 
was methylated in vitro by CpG or GpC methyltransferases, or when SacII sites were 489 
removed from pYBamy59 through site-directed mutagenesis, the transformation 490 
efficiency showed 8- to 15-fold increment as compared to the original plasmid (Kim et 491 
al., 2010). 492 
Another strategy to modify recombinant DNA before introduction into 493 
bifidobacterial cells was recently adopted in two independent studies (Yasui et al., 494 
2009; O’Connell-Motherway et al., 2009), with the aim to boost the transformation 495 
efficiency of B. adolescentis ATCC 15703 and B. breve UCC2003, respectively. In this 496 
strategy, a shuttle vector was pre-methylated in Escherichia coli cells carrying the 497 
genes encoding the DNA modification enzymes of the target Bifidobacterium before 498 
electroporation (Fig. 3). In fact, Yasui and coworkers (2009) developed a system called 499 
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”Plasmid Artificial Modification” (PAM) and demonstrated its efficacy for the target 500 
host B. adolescentis ATCC 15703, a strain that could be transformed only at an 501 
extremely low level. In the ATCC 15703 genome, they identified two Type II DNA 502 
methyltransferase genes, BAD_1233 and BAD_1383, which they cloned in E. coli 503 
TOP10 (Invitrogen) by means of a low copy number vector, obtaining the so-called 504 
“PAM host.” The E. coli TOP10 laboratory strain was shown to be the most suitable 505 
because it lacks the Type IV restriction enzymes mrr and mcrBC (which degrade DNA 506 
methylated by the R-M system of other bacteria) and the methylases dam, dcm, and 507 
hsdMS (which can make the DNA sensitive to possible Type IV restriction systems). 508 
Subsequently, an E. coli-Bifidobacterium shuttle vector, based on the pTB6 B. longum 509 
replicon (Tanaka et al., 2005), was introduced into the PAM host. Transformation 510 
efficiency improved considerably when B. adolescentis was electroporated with the 511 
shuttle vector DNA isolated from the PAM host, jumping from 1–3x100 to 105 512 
CFU/μg. This confirms that the shuttle vector was methylated by the modification 513 
enzyme encoded by the PAM plasmid in the E. coli host and consequently protected 514 
against restriction by B. adolescentis (Fig. 3). 515 
The same approach was adopted by O’Connell-Motherway et al. (2009) with B. 516 
breve UCC2003 as the target host. In the annotated genome of this strain, they found 517 
three different R-M gene clusters, including the methylase genes bbrIM, bbrIIM and 518 
bbrIIIM. The role of these modification genes in the acquisition of exogenous DNA by 519 
B. breve was studied in transformation experiments with pAM5-derived vectors (based 520 
on the pBC1 replicon from B. catenulatum; Álvarez-Martín et al., 2007b). The authors 521 
observed a 1000-, 10-, and 5-fold higher transformation frequency for pAM5 DNA 522 
isolated from E. coli expressing M.BbrIII, M.BbrII, and M.BbrI, respectively, which 523 
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indicates that, although differently, all three DNA methylation systems affected the 524 
transformation efficiency. 525 
The above studies demonstrated the usefulness of artificially modified DNA by 526 
means of the host methylases to increase the electroporation efficiency. Genome 527 
analyses and experimental data, however, have shown that Bifidobacterium strains 528 
harbour a very diverse range of R-M activities, even within the same species 529 
(O’Connell-Motherway et al., 2009). Therefore, this strategy is at least partly limited to 530 
the strains whose whole-genome sequence is known. To overcome this problem, 531 
O’Connell-Motherway et al. (2009) proposed the possibility of methylating exogenous 532 
DNA isolated from E. coli in vitro, through incubation of the DNA with cell extracts of 533 
the target host in the presence of S-adenosylmethionine. However, experimental data 534 
of the practicability and effectiveness of this strategy are not yet available. 535 
 536 
5.2. Conjugation in bifidobacteria 537 
The R-M barriers of a bacterial strain can also be bypassed by introducing foreign 538 
DNA through conjugation. Conjugation may occur when cis (oriT) and trans (transfer 539 
proteins, Mob and Tra) elements found in mobilizing plasmids are recognized by 540 
cellular components, which can be supplied by the host cell. Putative Mob and Tra 541 
protein coding genes and characteristic cis elements have been found in several 542 
bifidobacterial plasmids (O’Riordan and Fitzgeralds, 1999; Corneau et al., 2004; Gibbs 543 
et al., 2006; Shkoporov et al., 2008a; Table 1), suggesting their mobilization potential. 544 
Nevertheless, up to now, no DNA transfer system based on conjugation is available for 545 
members of the genus Bifidobacterium, and no conjugation events have been 546 
irrefutably demonstrated. The only documented systematic attempt to achieve 547 
conjugation in bifidobacteria was made by Shkoporov and collaborators (2008a), who 548 
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exploited the mobilization functions of three different Bifidobacterium plasmids to 549 
develop genetic tools based on the well characterized intergeneric conjugative element 550 
RP4 (IncPα) (Simon et al., 1983) to transfer DNA into B. pseudocatenulatum. They 551 
produced antibiotic-resistant clones that, though PCR-positive, did not contain the 552 
expected plasmid DNA. Consequently, development of effective conjugation systems 553 
for bifidobacteria, albeit potentially useful, remains in its infancy. 554 
 555 
5.3. Expression of heterologous genes among bifidobacteria 556 
The development of heterologous expression and secretion systems is strategically 557 
important for studying the properties of Bifidobacterium because of strain 558 
improvement and delivery into the human digestive tract of useful gene products such 559 
as vaccines or anticarcinogenic polypeptides. 560 
Heterologous genes from a diverse group of organisms have been expressed in 561 
bifidobacteria under the control of either heterologous or homologous promoters 562 
(Table 3). The current list includes genes and promoters mainly from Gram-negative 563 
and Gram-positive bacteria, but with exceptions, as the luciferase gene from 564 
Pyrophorus plagiophthalamus (Guglielmetti et al., 2008a) and several human genes 565 
(Xu et al., 2007). In addition to the genes reported in Table 3, several antibiotic 566 
resistance genes, used in preparing cloning and expression vectors, have been shown to 567 
be functional in bifidobacteria even under the control of their own regulatory elements. 568 
They include, for instance, the chloramphenicol acetyl transferase (cat) of the plasmid 569 
pC194, the erythromycin resistance gene of pE194 from Staphylococcus aureus, and 570 
the spectinomycin resistence gene from Enterococcus faecalis. In contrast, the 571 
thiostrepton resistance gene from Streptomyces is not functional in bifidobacteria 572 
(Rossi et al., 1998, Guglielmetti et al., 2007b). Similarly, the genes coding for 573 
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Pseudomonas fluorescens lipase, Bacillus licheniformis α-amylase and Streptomyces 574 
sp. cholesterol oxidase, are stably maintained in the bifidobacterial host, but under the 575 
control of their own promoters they are not expressed (Rossi et al., 1998). 576 
With respect to protein expression in bifidobacteria, excretion and secretion 577 
processes should be studied to develop export systems for expressed heterologous 578 
proteins or enzymes. In this context, MacConaill and collaborators (2003) investigated 579 
protein export in B. breve UCC2003 by means of the export-specific vector pFUN, 580 
based on the use of the staphylococcal nuclease (Nuc) as a reporter enzyme (Poquet et 581 
al., 1998). Due to the removal of its native signal peptide, the Nuc reporter protein is 582 
translocation-competent but unable to direct its own secretion. In this study, 583 
translational fusions were constructed with a nuc gene and the export signal provided 584 
by inserted B. breve chromosomal DNA fragments. By this strategy, seven signal 585 
peptides have been identified for B. breve UCC2003 (MacConaill et al., 2003). 586 
Recently, a secretion system has also been developed based on the α-amylase 587 
expression and secretion signals isolated from B. adolescentis INT57 (Park et al., 588 
2005b; Rhim et al., 2006). Park and collaborators constructed a secretion vector, 589 
pBESAF2, containing the promoter and the signal peptide of the α-amylase gene 590 
amyB. The gene encoding an intracellular phytase from E. coli was introduced in this 591 
vector and transcriptionally fused to the signal sequence and finally introduced by 592 
electroporation in B. longum MG1. The authors demonstrated that, by using this 593 
system, phytase enzyme was successfully expressed and secreted by B. longum into the 594 
culture broth. Furthermore, this system was employed for expression and secretion by 595 
B. longum MB1 of the bacteriocin pediocin PA-1 from Pediococcus acidilactici K10 596 
(Moon et al., 2005). 597 
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Analogously, Deng and collaborators (2009) selected through computational 598 
analysis the signal peptide sequence from the endo-1,5-α-L-arabinosidase gene of B. 599 
longum NCC2705, by which they obtain expression and secretion of the human 600 
interferon-α2b protein (IFN-α2b) in B. longum ATCC 15707. This study showed that 601 
65% of the total IFN-α2b was secreted from B. longum in the presence of the 602 
arabinosidase signal peptide, while only 15% of the protein was secreted without the 603 
signal peptide. Surprisingly, this experimentation was carried out without a 604 
conventional E. coli-Bifidobacterium shuttle plasmid, but by means of the commercial 605 
pBR322-based vector pBAD-gIIIA (Invitrogen), in which expression of the 606 
recombinant protein is arabinose-inducible by the presence of the promoter of the 607 
arabinose operon from E. coli. The maximal level of induction was obtained after 608 
addition of 0.2 % arabinose (Deng et al., 2009). Finally, Long et al. (2010) 609 
demonstrated that the exo-xylanase (XynF) signal peptide sequence from B. longum 610 
was suitable to guide secretion of the mature peptide of the human gut hormone 611 
oxyntomodulin. 612 
Information on regulated promoters, inducers, and repressors is extremely limited 613 
in bifidobacteria. Additional efforts are, therefore, needed to identify strong, weak, and 614 
regulated promoters for controlled gene expression in bifidobacteria under different 615 
environmental conditions. However, current knowledge on the expression of 616 
heterologous genes in Bifidobacterium has enabled development of reporter gene and 617 
drug delivery systems as potentially promising tools for future research and 618 
pharmaceutical applications. 619 
 620 
5.3.1. Reporter gene systems 621 
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Some reporter gene systems have already been developed and shown useful for 622 
several applications. To study promoter strength and regulation analysis or to identify 623 
genomic fragments containing active promoters, Klijn and co-workers (2006) 624 
developed the reporter vector pMDY23 based on the Escherichia coli β-glucuronidase 625 
gene gusA and the small cryptic B. longum plasmid pNCC293. After introducing the 626 
vector in B. longum NCC2705, they demonstrated the suitability of pMDY23 as a 627 
reporter plasmid for promoter study by analyzing the promoter activity of three DNA 628 
fragments (Klijn et al., 2006; Table 3). 629 
More recently, two studies showed the application of bioluminescence reporter 630 
genes in Bifidobacterium spp. (Guglielmetti et al., 2008a; Cronin et al., 2008). 631 
Guglielmetti and collaborators transformed by electroporation the human intestinal 632 
strain B. longum subsp. longum NCC2705 with a vector (pGBL8b) containing the 633 
insect luciferase gene lucGR from a click beetle (Pyrophorus plagiophthalamus). The 634 
same vector, however, was incapable of transforming B. animalis subsp. lactis BB12 635 
and B. bifidum MIMBb75 (Guglielmetti et al., 2008a; S. Guglielmetti, unpublished). 636 
The resulting bioluminescent B. longum was used to analyze variations in intracellular 637 
ATP concentration at acidic pH in the presence of different sugars, a technique proving 638 
to be a valuable tool for the rapid and sensitive study of the physiological state of 639 
bacterial cells under different environmental conditions. Nonetheless, the need to add 640 
exogenous D-luciferin as a substrate in this reporter system limits considerably its in 641 
vivo application. 642 
The bacterial luciferase system (coded by the luxABCDE operon) is generally less 643 
sensitive than insect luciferases, yet bacterial luciferase requires as substrate a long-644 
chain fatty aldehyde, which is intracellularly synthesized by a fatty acid reductase 645 
complex encoded by luxCDE. Therefore, the intracellular expression of the lux operon 646 
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circumvents the disadvantage of exogenous addition of luciferin and is thus more 647 
suitable for in vivo applications. Cronin et al. (2008) adopted the lux operon to develop 648 
the non-invasive luciferase reporter vector pLuxMC1, which was introduced in B. 649 
breve UCC2003. Once mice were orally inoculated with bioluminescent B. breve, the 650 
reporter system allowed a real-time tracking of the colonisation and persistence of this 651 
probiotic strain in vivo. 652 
 653 
5.3.2. Drug delivery systems 654 
Due to their safety and ability to colonize specific areas of the human 655 
gastrointestinal tract, bifidobacteria may turn out to be optimal vectors for in situ 656 
delivery of biologically active substances. Of particular interest is the fact that certain 657 
anaerobic bacteria, including species of Clostridium and Bifidobacterium, can 658 
selectively germinate and grow in the hypoxic regions of solid tumors (Malmgren and 659 
Flanigan, 1955; Kimura et al., 1980; Yazawa et al., 2000; Yazawa et al., 2001), such as 660 
those of most primary breast and uterine cervix cancers. This fact was exploited by the 661 
Japanese research team of Prof. Fujimori, who developed a strategy called 662 
“Bifidobacterial Selective Targeting” (BEST) (Fujimori, 2006). The Fujimori team’s 663 
BEST therapy involved the strain B. longum 105-A, which was genetically engineered 664 
via electro-transformation with pBLES100-S-eCD, a plasmid based on the shuttle 665 
vector pBLES100 (Matsumura et al., 1997) and comprising the cytosine deaminase 666 
gene (CD) under the hup gene promoter of B. longum (Nakamura et al., 2002; Table 3), 667 
which codes for a histone-like DNA-compacting protein. The CD enzyme converts the 668 
non-toxic prodrug 5-fluorocytosine (5-FC) to chemotherapeutic 5-fluorouracil (5-FU), 669 
which is systemically administrated to treat solid tumors. In conventional therapy, its 670 
clinical effectiveness is very limited by its high systemic toxicity, particularly toward 671 
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the bone marrow. Fujimori’s studies demonstrated that recombinant B. longum 672 
selectively produced CD in mammary tumor tissues in rats, and that CD could convert 673 
5-FC into 5-FU in vivo both after intratumoral injection and also by systemic 674 
administration (Sasaki et al., 2006). Furthermore, no adverse effects were observed in 675 
animal models during the use of B. longum as a gene delivery vector (Sasaki et al., 676 
2006), a finding supporting the potential effectiveness of this novel approach for 677 
cancer gene therapy in humans. More recently, it was developed an improved version 678 
of pBLES100-S-eCD, able to display 10-fold increased CD activity in B. longum 679 
(Hamaji et al., 2007). They demonstrated that the BEST approach works well even 680 
with a different bifidobacterial species, such as B. breve I-53-8w (Hidaka et al., 2007). 681 
Bifidobacteria have been used as a gene delivery vehicle of CD also by Chinese 682 
researchers, who expressed the CD gene in B. longum subsp. infantis by means of the 683 
vector pGEX-1λT. The recombinant bacterium was then used to inhibit melanoma in 684 
mice (Yi et al., 2005). As for the Invitrogen vector pBAD-gIIIA mentioned above, the 685 
functionality of the vector pGEX-1λT is surprising, because it carries no bifidobacterial 686 
replicon but only the pBR322 ori region. Moreover, Yi and collaborators claimed that 687 
the recombinant bifidobacteria were selected with ampicillin through the β-lactamase 688 
gene encoded by pGEX-1λT (Yi et al., 2005), an antibiotic marker generally 689 
considered not to be active in Gram-positives. The same research team used this 690 
approach to clone the Herpes simplex virus-thymidine kinase (HSV-TK) in B. longum 691 
subsp. infantis. In this system, the thymidine kinase expressed specifically in tumor 692 
tissues by bacterial cells, can convert the non-toxic precursor ganciclovir into the 693 
ganciclovir-3-phosphate, a toxic substance that kills the tumoral cells. The efficacy of 694 
this gene therapy system was demonstrated in vivo in a rat model of bladder cancer. 695 
After tail vein injection of 4.4 × 109 recombinant Bifidobacterium cells with a 696 
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concomitant daily intraperitoneal injection of Ganciclovir, on the 15th day after the 697 
beginning of the treatment, rat bladder tumor growth was inhibited (Tang et al., 2009). 698 
The BEST strategy was adopted also by Prof. Xu’s research team, who employed 699 
B. adolescentis and B. longum as gene delivery vectors to transport the anti-angiogenic 700 
factor endostatin into a hypoxic solid liver tumor in mice (Li et al., 2003, Fu et al., 701 
2005, Xu et al., 2007). Originally, they claimed that expression of the human liver 702 
endostatin gene was achieved in Bifidobacterium spp. by means of the expression 703 
plasmid pBV220. The vector pBV220 (Zhang et al. 1990) is a derivative of pBR322 704 
and contains PRPL promotors of the λ bacteriophage, the cI857ts gene encoding the 705 
temperature-sensitive λ repressor, and two strong transcriptional terminators 706 
(rrnBT1T2) of E. coli. This vector only contains the origin of replication of pBR322 707 
and a unique antibiotic selection for ampicillin (β-lactamase gene). As for the vectors 708 
pBAD-gIIIA and pGEX-1λT, it is therefore once again unexpected that pBV220 was 709 
found functional in bifidobacteria. The same authors reported, however, that this 710 
construct was highly unstable in B. longum (Xu et al., 2007). Therefore, it was 711 
modified by introducing the pMB1 Bifidobacterium replicon (Rossi et al., 1996) and a 712 
chloramphenicol resistance gene. The resulting vector, called pBV22210, was much 713 
more stably maintained in B. longum than pBV220 (Xu et al., 2007). Very recently, the 714 
plasmid pBV22210 has also been used in B. longum as an expression vehicle of the 715 
extracellular domain of TNF-related apoptosis-inducing ligand (TRAIL). The resulting 716 
recombinant strain was shown to have a specific antitumor effect on mouse 717 
osteosarcoma (Hu et al., 2009). In a following study, vector pBV22210 was also used 718 
to express in B. longum the granulocyte colony-stimulating factor (G-CSF), a molecule 719 
frequently used as a coadjuvant agent in tumor chemotherapy. When B. longum-720 
pBV22210-GCSF was applied to treat H22 and S180 sarcoma-bearing mice, it was 721 
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observed an effective antagonistic effect on bone marrow inhibited by 722 
cyclophosphamide and an over 65% inhibition of tumor growth (Zhu et al., 2009). 723 
Finally, the BEST strategy was adopted by Hou and colleagues (2006), who observed a 724 
significant inhibition of the growth of solid tumors in a knock-out mice lacking the 725 
phosphatase and tensin (PTEN) homolog with a genetically engineered B. longum, 726 
transformed with a pMB1-derived vector expressing the PTEN tumor suppressor gene 727 
under the hup gene promoter from B. longum. 728 
Other gene delivery systems have recently been developed in bifidobacteria. For 729 
instance, it was developed a vaccine delivery system based on B. animalis ATCC 730 
27536, genetically modified through transformation with the vector pBLES100, in 731 
which they cloned the flagellin gene fliC of Salmonella Typhimurium ATCC 14028 732 
under the B. longum hup gene promoter (Takata et al., 2006). Significantly higher 733 
levels of flagellin-specific IgA in the serum and stools of mice treated by oral 734 
administration of this recombinant B. animalis than in those treated with parental B. 735 
animalis, were detected (Takata et al., 2006). In a recent work, these authors studied 736 
the potential effectiveness of genetically modified bifidobacteria as oral vaccines by 737 
protecting mice from a lethal challenge with Salmonella in a typhoid fever model 738 
(Yamamoto et al., 2010). 739 
Another pioneering application of bifidobacteria as drug delivery system was that 740 
of Long and collaborators (2010), who developed engineered bifidobacteria as oral 741 
carriers of oxyntomodulin, a gut hormone that is used to reduce food intake and body 742 
weight through intravenous administration. Interestingly, the results of this study 743 
showed that oxyntomodulin-transformed B. longum reduced food intake, body weight 744 
and decreases blood lipid in overweight mice. The benefits were identical to those 745 
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obtained by oral administration of Orlistat, a gastrointestinal lipase inhibitor drug 746 
employed in obesity therapy (Long et al., 2010). 747 
As suggested by recent studies, bifidobacteria may also be used for the in situ 748 
delivery of human cytokines. The ani-inflammatory interleukin (IL)-10 has been 749 
expressed in its mature form by B. longum ATCC 15707 (Reyes Escogido et al., 2007; 750 
Table 3) and B. breve UCC2003 (Khokhlova et al., 2010). In the latter study, the gene 751 
coding for the mature form of human IL-10 was translationally fused to previously 752 
described Bifidobacterium signal peptides and placed under the control of 753 
bifidobacterial constitutive promoters. Specifically, a pB80 replicon-based shuttle 754 
vector carrying active promoter and terminator regions of B. longum gene hup, was 755 
used to clone gene IL-10, which was fused with the signal peptide regions of genes 756 
sec2, apuB or amyB, coding for B. breve secreted protein and extracellular 757 
amylopullulanase and B. adolescentis secreted alfa-amylase, respectively. Sec2 signal 758 
peptide was also placed under the control of constitutive promoter/terminator regions 759 
from B. longum gene gap, coding for enzyme glyceraldehyde-3-phosphate 760 
dehydrogenase. Interestengly, RT-qPCR experiments demonstrated that the expression 761 
level of IL-10 driven by gap promoter was higher than that under the control of hup 762 
promoter. Moreover, substitution of the Sec2 signal peptide-coding region with the 763 
signal sequence from amyB gene resulted in an intensely elevated level of IL-10 764 
mRNA (Khokhlova et al., 2010). 765 
 766 
5.4. Knock-out of bifidobacterial genes 767 
The prime method for studying the function of a gene and its impact on the overall 768 
cellular physiology and morphology consists in removing or disrupting the gene from 769 
its host (gene knock-out). This is generally accomplished by means of modification 770 
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systems based on homologous recombination. A low occurrence of homologous 771 
recombination has been reported in bifidobacteria, which agrees well with the absence 772 
of the major prokaryotic DNA recombination pathway encoded by recBCD in the 773 
genome of some strains, such as B. longum NCC2705 (Schell et al., 2002). As 774 
discussed previously, bifidobacteria display relatively low transformation efficiency. 775 
Evidently, the recombination frequency in Bifidobacterium is thus generally lower than 776 
that of transformation, limiting effective chromosomal integration of DNA. For these 777 
reasons, successful homologous recombination in bifidobacteria has only recently been 778 
reported. 779 
In 2008, it was published successful knockouts of B. breve UCC2003 genes by 780 
single-crossover recombination, employing two different strategies (O’Connel-781 
Motherway et al., 2008). First, O’Connel-Motherway and co-workers adopted a 782 
double-vector integration strategy to disrupt the amylopullulanase gene apuB. The first 783 
vector contained the origin of replication but lacked the rep gene coding for its 784 
replication protein (Ori+/Rep- vector). The second vector, bearing a different antibiotic 785 
resistance, was a derivative of the lactococcal temperature-sensitive plasmid pVE6007 786 
and harboured the rep gene of the former plasmid (Rep+ vector). An internal 1 kb 787 
DNA region of the apuB gene was cloned in the Ori+/Rep- plasmid, and both vectors 788 
(Ori+/Rep- and Rep+) were then introduced in B. breve UCC2003 under double 789 
antibiotic selection. In such recombinant cells, the Ori+/Rep- plasmid could replicate 790 
only in the presence of the other vector, which supplied the Rep protein in trans. Once 791 
the recombinant B. breve was cultivated at a high temperature (42 °C) and with 792 
selection only for the Ori+/Rep- vector, the Rep+ plasmid was lost from B. breve cells 793 
due to its temperature sensitivity and segregational instability. Accordingly, under 794 
selective conditions, the Ori+/Rep- plasmid has to integrate into the chromosome. 795 
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Thanks to this approach, the authors found by replica plaiting some B. breve apuB 796 
disruption isolates, which exhibited the expected phenotype and in which they verified 797 
plasmid integration by PCR and Southern hybridization. However, O’Connell-798 
Motherway and collaborators emphasized that this system is very tedious, time-799 
consuming, and unreliable (O’Connell-Motherway et al., 2008). 800 
In a later publication, the same researchers described insertional mutagenesis of 801 
the apuB gene and the endogalactanase gene (galA) of B. breve UCC2003 by means of 802 
plasmid methylation (O’Connell-Motherway et al., 2009). This strategy produced gene 803 
disruptions by single-crossover chromosomal integration of non-replicative plasmids 804 
containing internal fragments of 476 and 744 bp of the galA gene, and a 939 bp 805 
internal fragment of the apuB gene. These three plasmids were first introduced into an 806 
E. coli host harbouring two B. breve UCC2003 methylase genes (bbrIIM and bbrIIIM). 807 
The resulting methylated plasmids were then introduced into B. breve UCC2003 by 808 
electroporation. Antibiotic-resistant transformants were isolated for all methylated 809 
vectors at a frequency of up to 50 per μg of transformed DNA. No transformants were 810 
obtained when unmethylated constructs were introduced into strain UCC2003. The 811 
expected integration in the chromosome was finally verified by genetic and phenotypic 812 
analyses. These results by O’Connell-Motherway et al. (2009) showed that methylation 813 
of the non-replicating plasmid by B. breve UCC2003 methylases increased 814 
transformation efficiency to a level sufficiently high to allow site-specific homologous 815 
recombination to occur. This strategy has allowed the dissection of many genes from 816 
the UCC2003 strain, including gene components of clusters involved in utilization of 817 
ribose (Pokusaeva et al., 2010), insoluble cellulose (cellodextrin) (Pokusaeva et al., 818 
2011), and galactans (O’Connell Motherway et al., 2011b). 819 
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Also recently, Arigoni and Delley (2008) patented a gene deletion method in 820 
Bifidobacterium by two consecutive events of homologous recombination. The authors 821 
reported deletion of the tetracycline resistance gene tet(W) from B. animalis subsp. 822 
lactis NCC2818 (commercially known as strain BB12). Their method comprised the 823 
following steps. DNA fragments of approximately 3 kb flanking the tet(W) gene were 824 
amplified and joined via the start and stop codon of tet(W). The resultant 6 kb DNA 825 
fragment was cloned in pJL74 (LeDeaux and Grossman, 1995), a spectinomycin 826 
resistance vector unable to replicate in bifidobacteria; the resulting plasmid was 827 
introduced in B. animalis subsp. lactis NCC2818. Spectinomycin-resistant (specR) 828 
colonies were shown to harbour the plasmid integrated into the B. animalis 829 
chromosome via a single cross-over event. SpecR transformants were then cultivated 830 
for about 100 generations without antibiotic selection to promote loss of the plasmid. 831 
Spectinomycin-sensitive (specS) colonies were then selected by replica plating on MRS 832 
agar with or without added spectinomycin. Twenty-one percent of the tested colonies 833 
were specS, indicating that a second cross-over event had occurred, which resulted in 834 
excision of the vector from the chromosome. Finally, out of the 135 SpecS colonies 835 
tested by PCR, two had received the deletion of the tet(W) gene. The same strategy 836 
was used to delete a protease inhibitor (serpin-like) gene (BL0108) from B. longum 837 
NCC2705 with two positive recombinant colonies out of 12 colonies tested in the final 838 
PCR screening. This study showed for the first time an in frame deletion of a specific 839 
entire gene in Bifidobacterium, achieved by targeted double cross-over recombination. 840 
The application of plasmid artificial modification (PAM) system to this knock-out 841 
strategy is likely to be a powerful tool for future gene deletion/replacement in 842 
Bifidobacterium. 843 
 844 
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6. Concluding remarks and future perspectives 845 
A bunch of bifidobacterial plasmids have already been sequenced and analysed 846 
from several Bifidobacterium species, which has allowed the development of some 847 
rudimentary cloning and expression vectors. However, there is still a lack of 848 
knowledge about the basic biology of plasmids for them to be used with confidence. 849 
Dissection of translated and untranslated sequences will aid to define the functionality 850 
of the different plasmid elements found. This will help the designing of high-copy and 851 
low-copy number vectors for the fine-tuning expression of homologous and 852 
heterologous genes, while increasing stability of the constructs. Polishing and refining 853 
currently-in-use vectors and broaden their positive selection will also be useful for 854 
many molecular studies, as well as for the development of compatible systems 855 
allowing introduction of two vectors in a single cell. The construction of food-grade 856 
vectors, i.e. having no foreign DNA and free of antibiotic resistance makers, would 857 
further facilitate the future industrial use of genetically modified bifidobacteria. 858 
Nonetheless, at present, the lack of efficient gene knock-out protocols that can be 859 
efficiently applied to virtually all bifidobacterial species is the main limitation to the 860 
study of physiological and probiotic properties of bifidobacteria. Gene knock-out is, in 861 
fact, the golden procedure to unambiguously understand the role of a specific coding 862 
sequence. A few studies (Arigoni and Delley, 2008; O’Connell-Motherway et al., 863 
2008) demonstrated that standard knock-out procedures, based on homologous 864 
recombination, can be practicable in bifidobacteria, provided the frequency of 865 
transformation is sufficiently high. A suitable transformation rate could be potentially 866 
reached by combining different expedients, which can be deduced from the 867 
investigations presented in this review article, such as the use of strict anaerobic 868 
conditions during preparation of competent cells and electroporation (to increase 869 
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viability) and the employment of any possible strategy useful to overcome 870 
bifidobacterial restriction barriers. To this aim, it appears promising the set-up of 871 
protocols for the in vitro methylation of recombinant DNA before transformation, in 872 
spite of the improved transformation efficiency obtained by the laborious method of 873 
the PAM strategy. 874 
Nowadays, the European regulation concerning health claims on product labels 875 
(EC regulation 1924/2006) ratifies the need for an approval from the European Food 876 
Safety Authority (EFSA) for the efficacy of any specific probiotic product. As a 877 
consequence, industrial producers are demanding new efficient research instruments 878 
that can permit effective verification and demonstration of the health-promoting 879 
properties associated to probiotic microorganisms, such as bifidobacteria. In addition to 880 
technological reasons, such rapidly growing whole genome sequence data, the 881 
increasing interest of food and pharmaceutical industries on probiotics is boosting the 882 
research on bifidobacteria. It is, therefore, expected that in the next few years further 883 
steps will be done in the genetic modification of these organisms. 884 
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Figure Legends 1308 
Fig. 1. Trees produced by BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using a 1309 
pairwise alignment between a query (an arbitrarily selected Rep protein from a 1310 
Bifidobacterium plasmid) and the database sequences searched. Type I: this group 1311 
includes 18 Rep proteins from Bifidobacterium plasmids. Plasmids without species 1312 
indication belong to Bifidobacterium longum susp. longum. Types II-VI: Rep stands for 1313 
replication initiation protein. Types II and IV: Bifidobacterium longum stands for 1314 
Bifidobacterium longum susp. longum. CFB stands for the bacterial group Cytophaga–1315 
Flavobacterium–Bacteroides. Red triangles evidence Rep proteins from 1316 
Bifidobacterium plasmids. 1317 
Fig. 2. Linear functional maps of a representative plasmid from all the Bifidobacterium 1318 
plasmid structures up to now recognized (in accordance with Table 1). In these maps, 1319 
all the open reading frames from Bifidobacterium plasmids with a putatively assigned 1320 
biological function are included. Dotted arrows refer to hypothetical conserved 1321 
proteins with unknown function. Genes represented with the same colors/motif share a 1322 
significant sequence similarity. Genes represented with white arrows are harbored by 1323 
only one of the shown plasmids. Rep typology in accordance to Fig. 1 is indicated 1324 
between brackets. 1325 
Legend of the gene symbols indicated in the maps. rep, gene encoding a 1326 
replication initiation protein. mob, gene encoding a putative plasmid mobilization 1327 
protein. memb, gene encoding an integral transmembrane protein. tnpB, gene encoding 1328 
for the transposase of an insertion sequence-like element of the IS200/IS605 family, 1329 
named ISBlo15. tra, transposase gene. trw, gene encoding for a putative protein 1330 
containing the conjugative relaxase domain TrwC/TraI (Conserved Domain Database, 1331 
CDD, accession code TIGR02686). ftsK-like gene, gene putatively encoding for a 1332 
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domain of the FtsK/SpoIIIE family. This domain contains a putative ATP binding P-1333 
loop motif. A mutation in FtsK causes a temperature sensitive block in cell division 1334 
and it is involved in peptidoglycan synthesis or modification. The SpoIIIE protein is 1335 
implicated in intercellular chromosomal DNA transfer (CDD accession code 1336 
pfam01580). tet(Q), tetracycline resistance gene encoding a ribosomal protection 1337 
protein. copG, orf ecoding a putative protein that shares similarity with the plasmid 1338 
pMV158-encoded transcriptional repressor CopG (CDD accession code pfam01402). 1339 
par, gene encoding for a putative protein belonging to the ParA conserved family of 1340 
bacterial proteins (CDD accession code cd02042), implicated in chromosome 1341 
segregation (involved in the plasmid replication and partition). RE gene, gene encoding 1342 
a putative protein with a type II restriction endonuclease domain (EcoRII, CDD 1343 
accession code pfam09019). peptidase gene, encoding for a putative member of 1344 
peptidase family C39 (cd02549). Peptidase family C39 mostly contains bacteriocin-1345 
processing endopeptidases from bacteria. mobA and mobB, mobilization protein genes 1346 
harbored by plasmids from the Cytophaga–Flavobacterium–Bacteroides group of 1347 
bacteria. 1348 
Fig. 3. Strategies for the preparation of vector DNA to introduce by electroporation in 1349 
bifidobacteria. (A) Conventional strategy, involving the extraction of shuttle vector 1350 
DNA from E. coli and direct introduction in Bifidobacterium cells. (B) Plasmid 1351 
Artificial Modification (PAM) strategy: 1 – preparation of the PAM host, consisting of 1352 
an appropriate E. coli strain (e.g. E. coli TOP10) harbouring PAM vector (a low copy 1353 
number vector coding for the methylase(s) of the target host); 2 – introduction of an E. 1354 
coli-Bifidobacterium shuttle vector into the PAM host; 3 – modification of shuttle 1355 
vector DNA by methylase(s) coded by PAM vector; 4 – extraction of the now 1356 
methylated vector and 5 – introduction into the target host (Bifidobacterium) by 1357 
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electroporation; 6 – target host restriction system(s) cannot digest the methylated 1358 
shuttle vector; 7 – shuttle vector replicates inside target host.1359 
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Table 1. Plasmids of Bifidobacterium species whose whole nucleotide sequence is known. 1360 
Bifidobacterium species1 Strain Plasmid Size (bp) 
Putative replication 
mechanism (Rep type2) Reference/GenBank accession number 
      
B. asteroides DSM20089 pCIBAO89 2111 Theta (II) Cronin et al. 2007 / EU030683 
B. asteroides DSM20089 pAP1 2140 Theta (II) Y11549 
B. bifidum B80 pB80 4898 RC (Ia) Shkoporov et al. 2008a / DQ305402 
B. bifidum CCTCC M203049 pBIF10 9275 RC (IV) DQ093580 
B. breve NCFB2258 pCIBb1 5750 RC (III) O’Riordan and Fitzgerald 1999 / AF085719 
B. breve B21a pB21a 5206 RC (III) Shkoporov et al. 2008a / DQ497626 
B. breve - pNBb1 2297 RC (III) E17316 
B. catenulatum L48 pBC1 2540 Theta (V) Alvarez-Martin et al. 2007 / DQ011664 
B. longum KJ pKJ36 3625 RC (Ib) Park et al. 1997 / AF139129  
B. longum KJ pKJ50 4960 RC (Ia) Park et al. 1999 / BLU76614 
B. longum NCC2705 pBLO1 3626 RC (Ib) Schell et al. 2002 / AF540971 
B. longum MG1 pMG1 3682 RC (Ib) Park et al. 2003 / AY210701 
B. longum RW048 pNAC1 3538 RC (Ia) Corneau et al. 2004 / AY112724 
B. longum RW041 pNAC2 3684 RC (Ib) Corneau et al. 2004 / AY112723 
B. longum RW041 pNAC3 10224 Theta (II) Corneau et al. 2004 / AY112722 
B. longum BK51 pTB6 3624 RC (Ib) Tanaka et al. 2005 / AB187597  
B. longum B2577 pMB1 1847 Theta (V) Rossi et al. 2006 / X84655 
B. longum DJO10A pDOJH10L3 10073 Theta (II) Lee and O’Sullivan 2006 / AF538868 
B. longum DJO10A pDOJH10S 3661 Theta (V) Lee and O’Sullivan 2006 / AF538869 
B. longum NAL8 pNAL8L 3489 RC (Ia) Guglielmetti et al. 2007 / AM183145 
B. longum NAL8 pNAL8M 4910 RC (Ia) Guglielmetti et al. 2007 / AM183144 
B. longum VMKB44 pB44 3624 RC (Ib) Shkoporov et al. 2008a / AY066026 
B. longum FI10564 pFI2576 2197 Theta (V) Moon et al. 2009 / DQ452864 
B. longum BK28 pBK283 4537 RC (Ia) Fukiya et al. 2010 / AB495342 
B. longum DPC6043 p6043A 4896 RC (Ia) DQ458911 
B. longum DPC6043 p6043B 3680 RC (Ib) DQ458910 
B. longum M62 pSP02 4896 RC (Ia) GU256055 
B. pseudocatenulatum VMKB4M p4M 4488 RC (VI) Gibbs et al. 2006 / AF359574 
B. pseudolongum subsp. globosum DPC479 pASV479 4815 RC (III) Sangrador-Vegas et al. 2007 / DQ103758 
Bifidobacterium sp. A24 pBIFA24 4892 RC (Ia) Park et al. 2008 / DQ286581 
1B. longum stands for Bifidobacterium longum subsp. longum. 2Replication protein typology of RC- (rolling-circle) and theta-type plasmids is in accordance 1361 
with dendrograms in Fig. 1. 3DNA sequence assessment suggests that pDOJH10L is a cointegrate involving plasmids very similar to pKJ50 (96% identity) and 1362 
pNAC2 (98% identity). 1363 
 1364 
 1365 
 1366 
 1367 
 1368 
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Table 2.- Summary of protocols for electrotransformation (electroporation) of bifidobacteria. 1369 
Vector 
(size, kb) 
(marker) 
Replicon(s) Growth medium1 Washing buffer 
Electroporation 
buffer Preincubation
2
 
Voltage and 
resistance 
Recovering 
medium  
Transformation rate 
(transformants/μg DNA) Reference 
          
pDG7 
(7.3 kb) 
(CmR) 
pMB1- 
pBR322 
MRS, 0.5 M sucrose, 
0.05% cysteine-HCl 
(OD600 nm 0.2) 
0.5 M sucrose 
1 mM ammonium 
citrate buffer pH6, 
0.5 M sucrose  
3.5 h at 4°C in 
electroporation 
buffer 
12 kV/cm, 
200 Ω 
MRS, 
0.5 M sucrose, 
0.05% cysteine 
B. animalis ATCC 27536   5.0x103  
B. breve   4 1.3x104 
B. breve AS   2.0x102 
B. bifidum U3   3.0x102 
B. bifidum ATCC 15696   7.4x103 
B. infantis U1   2.5x102 
B. infantis ATCC 27920   4.0x104 
B. longum U2   2.6x103 
B. longum Wiesby 2   7.0x104 
Argnani et 
al. 1996 
          
pNC7 
(4.9 kb) 
(CmR) 
pMB1 (non 
replicative 
in E. coli) 
Iwata Medium (IM; 
Iwata and Morishita, 
1989), 
16% ActilightP 
(OD600 nm 0.2-0.3) 
5 mM K-
phosphate 
buffer pH7 
KMR buffer (5 
mM KH2PO4, 1 
mM MgCl2, 0.3 M 
raffinose, pH 4.8) 
Overnight at 
0°C in 
electroporation 
buffer 
12.5 kV/cm, 
200 Ω 
IM, 
16% ActilightP 
 
B. animalis ATCC 27536   3.0x104  
B. breve MB226   6.6x104 
B. breve MB252   2.3x104 
B. bifidum MB254   7.2x104 
B. infantis MB208   1.2x105 
B. infantis MB263   9.3x103 
B. longum MB231   2.8x102 
B. pseudocatenulatum MB264 5.0x101 
B. ruminale MB266   7.2x102 
B. dentium MB269   3.6x101 
B. magnum MB267   1.8x103 
Rossi et al. 
19973 
          
pRM2 
(7.5 kb) 
(SpR) 
pMB1- 
pBR322 
TPY + glucose 
(OD660 nm 0.6) 
 
10% glycerol 10% glycerol 
Freezing at 
-135°C and 
storage at  
-70 °C 
10 kV/cm, 
200 Ω 
TPY + glucose 
 
B. longum B2577   3.8x102 Missich et 
al. 1994 
          
pBLES100 
(9.1 kb) 
(SpR) 
pTB64- 
pBR322 
Briggs Medium 
(Briggs, 1953) 
supplemented with 
2% lactose instead of 
glucose 
(cells in middle to 
late log phase) 
10% glycerol 10% glycerol 
Freezing at 
-135°C and 
storage at  
-70 °C 
10 kV/cm, 
200 Ω Briggs Medium B. longum 105-A   2.2x10
4
 
Matsumura 
et al. 1997 
     
pBKJ50F 
(8.1 kb) 
(CmR) 
pKJ50- 
pBR322 According to Argnani et al. (1996). with the only modification of pulse at 10 kV/cm B. animalis ATCC 27536   2.0x10
2
 
Park et al. 
1999 
     
pBES2 
(7.6 kb) 
(CmR) 
pMG14- 
pUC 
(ColE1) 
According to Argnani et al. (1996), with the addition of Oxyrase® (Oxyrase inc. Ohio) in the recovering medium B. longum MG1   7.3x103 Park et al. 2003 
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pBRASTA101 
(5.0 kb) 
(SpR) 
pTB64- 
pUC 
(ColE1) 
According to Missich et al. (1994) and Matsumura et al. (1997) B. longum 105-A   2.5x106 Tanaka et 
al. 2005 
          
pFUN 
(8.1 kb) 
(EryR) 
pAMβ1- 
(E. faecalis) 
pBluescript 
(ColE1) 
IM, 
(Mid-log phase cells, 
OD600 nm 0.5 to 0.7) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
- 
10 kV/cm, 
200 Ω Iwata Medium B. breve UCC2003   10
2
-103 MacConaill 
et al. 2003 
          
pPKCm1 
(6.2 kb) 
(CmR)  
pCIBA089- 
pBluescript 
(ColE1) 
IM, 
(Mid-log phase cells, 
OD600 nm 0.5 to 0.7) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
- 
10 kV/cm, 
200 Ω Iwata Medium 
B. breve UCC2003   3.8x106 
B. animalis subsp. lactis   101 
B. longum NCIMB8809   102 
B. pseudolongum NCIMB2244   102 
B. globosum JCM5820   103 
B. pseudocatenulatum LMG10505  103 
B. dentium NCFB2843   104 
Cronin et 
al. 2007 
          
pASV480 
(9.0 kb) 
(CmR) 
pASV479-
pBluescript 
(ColE1) 
 
IM, 
(Mid-log phase cells, 
OD600 nm 0.5 to 0.7) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
- 
10 kV/cm, 
200 Ω 
Reinforced 
Clostridial 
Medium 
(RCM) 
B. breve NCIMB 8807   ~105 
B. breve NCFB 2258   ~105 
Sangrador-
Vegas et al. 
2007 
          
pAM4 
(7.6 kb) 
(TetR) 
pBC1- 
pUC 
MRS, 
0.05% cysteine 
(Mid-log phase cells, 
OD600 nm 0.5 to 0.7) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
0.5 M sucrose, 
1 mM citrate 
buffer (pH 5.8) 
20 min in ice 10 kV/cm, 200 Ω 
Reinforced 
Clostridial 
Medium 
(RCM) 
 
B. adolescentis LMG10502   9.2x102 
B. animalis LMG10508   4.0x101 
B. animalis subsp. lactis Bb12  1.6x102 
B. breve LMG13208   1.0x102 
B. breve UCC2003   1.4x102 
B. dentium F101   9.5x101 
B. longum L25   6.6x101 
B. pseudolongum LMG11571   6.3x101 
B. pseudocatenulatum M115   1.0x105 
B. thermophilus LMG11571   4.6x101 
C. glutamicum LMG19741   3.0x100 
Álvarez-
Martín et 
al. 2008 
          
1Phase of growth at which bifidobacterial cells are collected before washing steps. 1370 
2Incubation step of competent cells before electroporation or storing at -80°C. 1371 
3Trasformation experiments were performed with vector DNA isolated from B. animalis MB209. 1372 
4pTB46 and pMG1 plasmids are isogenic to pB44, pNAC2, pBLO1, pDOJ10L, and pKJ36. 1373 
B. animalis ATCC 27536 is also known as B. animalis MB209; B. infantis stands for Bifidobacterium longum subsp. infantis. 1374 
Key of antibiotic markers: CmR, chloramphenicol acetyl transferase (cat); TetR, tetracycline resistance [tet(W)]; SpR, spectinomycin resistance; EryR, erythromycin 1375 
resistance. 1376 
 1377 
1378 
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Table 3.- Expression of heterologous genes in bifidobacteria. 1379 
Protein (gene) Origin Expression host Promoter Reference(s) 
Cytosine deaminase E. coli B. longum 105-A Promoter of hup gene, coding for the histone like protein of B. longum Nakamura et al. 2002 
Secreted nuclease (nuc) Staphylococcus aureus B. breve UCC2003 Seven different promoters from B. breve UCC2003 MacConaill et al. 2003 
Endostatin (Liver cDNA); TNF-related 
apoptosis-inducing ligand (TRAIL) Human B. adolescentis; B. longum Coliphage lambda PRPL promoter regions 
Li et al. 2003; Fu et al. 2005; 
Xu et al. 2007; Hu et al., 2009 
Phytase (appA) fused with the signal 
sequence of the amyB gene from B. 
adolescentis Int-57 
E. coli MC4100 B. longum MG1 Promoter of the amyB gene from B. adolescentis Int-57 Park et al. 2005b 
Green fluorescent protein (gfp) Vector pEGFP (Clontech, USA) B. longum MG1 
Expressed with two promoters from Bifidobacterium spp. GE65 
(sequence analysis revealed similarity with Lactobacillus johnsonii) Ji et al. 2005 
Glutamate decarboxylase Rice B. longum MG1 Not known Park et al. 2005a 
Flagellin (fliC) 
Salmonella 
Typhimurium 
ATCC14028 
B. animalis ATCC27536 Promoter of hup gene from B. longum Takata et al. 2006; Yamamoto 
et al., 2010 
 β-glucuronidase (gusA) E. coli B. longum NCC2705 Putative promoters of genes BL1363, BL1613 and BL1518 from B. longum NCC2705 Klijn et al. 2006 
PTEN tumor suppressor Human B. longum L17 Promoter region of hup gene from B. longum Hou et al. 2006 
Interleukin-10 (rhIL-10) Human B. longum ATCC15707 Promoter and terminator sequences from hup gene from B. longum NCC2705 Reyes Escogido et al. 2007 
Interleukin-10 (hIL-10) Human B. breve UCC2003 Promoters of  hup and gap genes from B. longum Khokhlova et al., 2010 
β-glucuronidase (gusA) E. coli (from pNZ272) B. breve NCIMB 8807 rRNA gene promoter from B. breve 8807 Sangrador-Vegas et al. 2007 
Luciferase (lucGR) Pyrophorus plagiophthalamus B. longum NCC2705 Promoter from phage T5 Guglielmetti et al. 2008 
Cholesterol oxidase (choPA operon) Streptomyces spp. B. longum MG1 16S rRNA gene promoter from B. longum MG1 Park et al. 2008 
α-l-arabinofuranosidase (abfB) B. longum B667 B. pseudocatenulatum M115 Native Álvarez-Martín et al. 2008 
Bacterial luciferase (luxABCDE operon) Photorhabdus luminescens B. breve UCC2003 
repC promoter from B. catenulatum plasmid pBC1 and promoter 
Phelp from Listeria monocytogenes Cronin et al. 2008 
Bile resistance mechanism BilE (bilE 
operon) 
L. monocytogenes 
EGD-e B. breve UCC2003 Native Watson et al. 2008 
Synthetic human fibroblast growth 
factor (FGF-2) fused with signal peptide 
of Sec2 from B. breve UCC2003 
pkFGFB B. breve UCC2003 
Promoter and terminator regions of hup gene from B. longum 
VMKB44 Shkoporov et al. 2008b 
Promoter/TIR of B. longum VMKB44 gene gap 
Interferon-α2b Human B. longum ATCC 15707 E. coli araBAD promoter from commercial vector pBAD-gIIIA Deng et al. 2009; Yu et al., 2010, 2011 
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Thymidine kinase Herpes simplex B. infantis tac promoter of commercial vector pGEX-5X-1 Tang et al. 2009 
Granulocyte colony-stimulating factor 
(GCSF) Human B. longum Coliphage lambda PRPL promoter regions Zhu et al. 2009 
Oxyntomodulin (OXM) Human B. longum NCC2705 E. coli araBAD promoter Long et al. 2010 
Interleukin-12 (mIL-12) Mouse B. longum NCC2705 E. coli araBAD promoter from commercial vector pBAD-gIIIA Yu et al., 2012 
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Fig. 2 1385 
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Fig. 3 1388 
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